-
Je něco špatně v tomto záznamu ?
The evaluation of neuroprotective efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-poisoned rats
Kassa J, Karasova J, Vasina L.
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie
PubMed
17685413
DOI
10.1002/jat.1273
Knihovny.cz E-zdroje
- MeSH
- acetylcholinesterasa metabolismus MeSH
- antidota farmakologie terapeutické užití MeSH
- atropin farmakologie terapeutické užití MeSH
- autonomní nervový systém účinky léků MeSH
- butany farmakologie MeSH
- časové faktory MeSH
- čití, cítění účinky léků MeSH
- financování organizované MeSH
- krysa rodu rattus MeSH
- modely nemocí na zvířatech MeSH
- neuroprotektivní látky farmakologie terapeutické užití MeSH
- neurotoxické syndromy enzymologie epidemiologie patofyziologie prevence a kontrola MeSH
- obidoxim chlorid farmakologie MeSH
- organofosforové sloučeniny MeSH
- otrava organofosfáty MeSH
- oximy farmakologie terapeutické užití MeSH
- pohybová aktivita účinky léků MeSH
- potkani Wistar MeSH
- pyridinové sloučeniny farmakologie MeSH
- reaktivátory cholinesterasy farmakologie terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- srovnávací studie MeSH
The neuroprotective effects of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in combination with atropine in rats poisoned with cyclosarin were studied. The cyclosarin-induced neurotoxicity was monitored using a functional observational battery at 24 h and 7 days following cyclosarin challenge. The results indicate that the oxime HI-6 combined with atropine seems to be the most effective antidote for a decrease in cyclosarin-induced neurotoxicity. Both newly developed oximes (K074, K075) as well as obidoxime are also able to counteract cyclosarin-induced acute neurotoxicity, but their neuroprotective potency is significantly lower compared with the oxime HI-6. Therefore, the oxime HI-6 is still the most suitable oxime for the antidotal treatment of acute poisonings with cyclosarin due to its neuroprotective as well as reactivating efficacy.
Citace poskytuje Crossref.org
- 000
- 01832naa 2200277 a 4500
- 001
- bmc10013317
- 003
- CZ-PrNML
- 005
- 20250521161112.0
- 008
- 100603s2007 xxu e eng||
- 009
- AR
- 024 __
- $a 10.1002/jat.1273 $2 doi
- 035 __
- $a (PubMed)17685413
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kassa, Jiří, $d 1956- $7 mzk2003181395
- 245 14
- $a The evaluation of neuroprotective efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-poisoned rats / $c Kassa J, Karasova J, Vasina L.
- 314 __
- $a Department of Toxicology, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic. kassa@pmfhk.cz
- 520 9_
- $a The neuroprotective effects of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in combination with atropine in rats poisoned with cyclosarin were studied. The cyclosarin-induced neurotoxicity was monitored using a functional observational battery at 24 h and 7 days following cyclosarin challenge. The results indicate that the oxime HI-6 combined with atropine seems to be the most effective antidote for a decrease in cyclosarin-induced neurotoxicity. Both newly developed oximes (K074, K075) as well as obidoxime are also able to counteract cyclosarin-induced acute neurotoxicity, but their neuroprotective potency is significantly lower compared with the oxime HI-6. Therefore, the oxime HI-6 is still the most suitable oxime for the antidotal treatment of acute poisonings with cyclosarin due to its neuroprotective as well as reactivating efficacy.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antidota $x farmakologie $x terapeutické užití $7 D000931
- 650 _2
- $a atropin $x farmakologie $x terapeutické užití $7 D001285
- 650 _2
- $a autonomní nervový systém $x účinky léků $7 D001341
- 650 _2
- $a butany $x farmakologie $7 D002073
- 650 _2
- $a reaktivátory cholinesterasy $x farmakologie $x terapeutické užití $7 D002801
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pohybová aktivita $x účinky léků $7 D009043
- 650 _2
- $a neuroprotektivní látky $x farmakologie $x terapeutické užití $7 D018696
- 650 _2
- $a neurotoxické syndromy $x enzymologie $x epidemiologie $x patofyziologie $x prevence a kontrola $7 D020258
- 650 _2
- $a obidoxim chlorid $x farmakologie $7 D009768
- 650 _2
- $a organofosforové sloučeniny $7 D009943
- 650 _2
- $a oximy $x farmakologie $x terapeutické užití $7 D010091
- 650 _2
- $a pyridinové sloučeniny $x farmakologie $7 D011726
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a čití, cítění $x účinky léků $7 D012677
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a otrava organofosfáty $7 D062025
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Žďárová Karasová, Jana, $d 1982- $7 xx0099787
- 700 1_
- $a Vašina, Libor $7 xx0332175
- 773 0_
- $w MED00008416 $t JAT. Journal of applied toxicology $g Roč. 27, č. 6 Nov-Dec (2007), s. 621-630 $x 0260-437X
- 910 __
- $a ABA008 $b x $y 8 $z 0
- 990 __
- $a 20100602090911 $b ABA008
- 991 __
- $a 20250521161109 $b ABA008
- 999 __
- $a ok $b bmc $g 749176 $s 612812
- BAS __
- $a 3
- BMC __
- $a 2007 $b 27 $c 6 Nov-Dec $d 621-630 $i 0260-437X $m JAT. Journal of applied toxicology $n J Appl Toxicol $x MED00008416
- LZP __
- $a 2010-B2/vtme
